Fig. 1.

Proportion of patients reporting improvements ≥ MCID and NNTs in PROs at week 14 (NRI-MI). *p < 0.05, ^†p ≤ 0.01, and ^‡p ≤ 0.001 versus placebo. p values nominal. NRI-MI is non-responder imputation (NRI) incorporating multiple imputation (MI) to handle missing data due to COVID-19. MCID definitions: BASDAI, ≥ 1.1-point decrease; PtGA, total back pain and nocturnal back pain, ≥ 1-point decrease; FACIT-F, ≥ 4-point increase; BASFI, ≥ 0.6-point increase; ASAS HI and ASQoL, ≥ 3 points decrease;SF-36 PCS and MCS, ≥ 2.5-point increase; WPAI presenteeism and activity impairment, ≥ 20-point decrease; WPAI overall work impairment, ≥ 15-point decrease; WPAI absenteeism, MCID not available. ASAS HI Assessment of SpondyloArthritis international Society Health Index, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, MCID minimal clinically important difference, MCS mental component summary, NNT number needed to treat, NRI non-responder imputation, PBO placebo, PCS physical component summary, PROs patient-reported outcomes, PtGA Patient Global Assessment of Disease Activity, SF-36 36-Item Short Form Health Survey, UPA upadacitinib, WPAI Work Productivity and Activity Impairment